Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

474
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
474
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

433
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
433
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

2.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
2.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

2.6K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.6K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sex-specific cellular and molecular mechanisms of PFAS-induced reproductive toxicity.

Toxicology·2026
Same author

<i>In silico</i> approach towards nanostructuring of dysprosium bis(amide)-alkene based single-ion magnet onto 1D, 2D, and 3D Network.

Physical chemistry chemical physics : PCCP·2026
Same author

Right Atrial Myxoma With Dual Coronary Artery Feeding: A Vascular Surprise.

JACC. Case reports·2026
Same author

Ellis-van Creveld Syndrome: Common Atrium with Post-axial Polydactyly.

QJM : monthly journal of the Association of Physicians·2026
Same author

Probiotic properties of <i>Bacillus subtilis</i> isolates from neonatal meconium.

Frontiers in microbiology·2026
Same author

When the left ventricle dances: ballerina foot appearance in hypertrophic cardiomyopathy.

The Journal of invasive cardiology·2026
Same journal

Retraction: The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia.

Cureus·2026
Same journal

Patient-Reported Understanding of Emergency Department Discharge Instructions, Satisfaction, and Acceptability of a Future Telemedicine-Based Call-Back Program: Phase 1 Observational Pilot Study at a Tertiary Hospital in Dubai, United Arab Emirates.

Cureus·2026
Same journal

Correction: Methylprednisolone-Induced Delayed and Sustained Bradycardia in Multisystem Inflammatory Syndrome in Children.

Cureus·2026
Same journal

Rapid Interval Development of a Left Hepatic Artery Pseudoaneurysm During Acute Interstitial Edematous Pancreatitis.

Cureus·2026
Same journal

Recurrent Acute Pancreatitis Secondary to Untreated Hyperparathyroidism: A Case Report and Literature Review.

Cureus·2026
Same journal

A Prospective Case-Control Study of Helicobacter pylori and Systemic Inflammation in Colorectal Cancer Pathogenesis.

Cureus·2026
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.2K

提卡格勒尔诱导的完整的心脏阻塞

Zubair Farooq1, Saurabh Kumar Singh2,3, Shrividya Rao4

  • 1Cardiology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, IND.

Cureus
|November 27, 2025
PubMed
概括
此摘要是机器生成的。

提卡格勒勒可以在心肌梗塞后的年轻患者中引起完全的心脏阻塞 (CHB). 及时识别和切换抗血小板治疗可以解决CHB并挽救生命.

关键词:
完全阻止了心脏的阻塞.起器是一种心脏起器.这是一种可逆的可逆性.这就是Ticagrelor.这是一个短暂的过渡.

更多相关视频

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.5K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K

相关实验视频

Last Updated: Jan 10, 2026

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.5K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 前壁心肌梗塞 (AWMI) 是一种严重的心脏事件.
  • 穿皮冠状动脉干预 (PCI) 是对AWMI的常见治疗方法.
  • 双抗血小板治疗 (DAPT) 是PCI后的标准护理.

研究的目的:

  • 报告一个罕见的蒂卡格勒罗尔诱导的完全心脏阻塞 (CHB) 病例.
  • 强调在年轻患者中识别药物诱导的CHB的重要性.

主要方法:

  • 一名患有AWMI的年轻男性接受了PCI,并开始接受DAPT (阿司匹林和提卡格勒罗).
  • 患者出现了昏迷和CHB,需要临时节奏.
  • 切断了提卡格勒罗的治疗,并用克洛皮多格雷尔取代.

主要成果:

  • 患者在断药后40小时内经历了CHB的完全消失.
  • 在切换抗血小板治疗后,没有进一步的CHB发作.
  • 冠状动脉扫描证实了专利支架,没有其他心脏异常.

结论:

  • 提卡格勒可以诱导CHB,即使在没有先前导电问题的年轻人中也是如此.
  • 早期发现和治疗药物诱导的CHB对于患者的治疗结果至关重要.
  • 切换到另一种抗血小板药物可以有效地管理提卡格雷勒诱导的CHB.